| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Apr 19, 2022Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancerCoeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq:...
-
Apr 13, 2022
Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional preclinical programs advancing in neutropenia and anemia in cancer patients WEXFORD
-
Jan 20, 2022Newly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI)
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board...
-
Aug 19, 2021Technologies include CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a pharmaceutical company focused on the development of innovative technologies designed to disrupt conventional treatment paradigms and improve patient...
-
Jul 9, 2021New Corporate Name and Updated Stock Ticker Symbol Highlight Company's Brand Transformation
Vinings Holdings, Inc. (OTC PINK: NDYN), today announced that it is changing its corporate name to "Coeptis Therapeutics, Inc." and updating its ticker symbol to "COEP" effective Monday, July 12,...